Africa is where the next decade of clinical research gets done.
A young, genetically diverse population, high disease burden, and a fast-maturing regulatory landscape make Africa one of the most underused opportunities in global clinical research and Voitheia is built to help sponsors move on it.
A patient population global trials rarely reach.
Enrollment timelines other regions can’t match.
High-Volume Disease Burden
Large, well-documented patient pools across cardiometabolic, infectious disease, oncology and maternal health indications.
Faster Enrollment Timelines
Dense urban teaching-hospital catchments and centralized referral patterns shorten the path to full enrollment.
Treatment-Naive Populations
Lower prior trial exposure in many markets improves signal quality, particularly for early-phase studies.
Multi-Country Scalability
One credentialed network spanning multiple countries, instead of separate site-identification efforts per market.
Meaningfully lower per-patient costs, without cutting corners on quality.
Lower site overhead, competitive investigator and staff costs, and high-volume patient access combine to reduce total study cost relative to saturated trial markets — while every site in our network is held to the same GCP standard sponsors require anywhere else in the world.
A regulatory environment that’s maturing fast.
NAFDAC
Nigeria's National Agency for Food and Drug Administration and Control oversees clinical trial authorization and GCP compliance.
AVAREF
The African Vaccine Regulatory Forum coordinates joint regulatory and ethics review across participating African states.
African Medicines Agency
A continental framework working toward harmonized regulatory standards and faster multi-country approvals.
WHO Prequalification
Alignment with WHO prequalification pathways supports downstream access once a therapy is approved.
Why we started in Nigeria and why it scales from here.
Nigeria is Africa’s most populous nation, its largest economy, and home to a dense network of teaching hospitals and universities with decades of clinical trial experience. English is the language of instruction and regulatory filing, and NAFDAC’s framework is one of the continent’s most established.
That combination makes Nigeria the natural anchor for a pan-African network a proven base of credentialed sites and investigators that Voitheia is extending outward to Ghana, Kenya and beyond, one verified partner at a time.
- Africa's largest population and economy
- English-language regulatory and clinical documentation
- An established NAFDAC regulatory framework
- A dense, credentialed teaching-hospital network
- Voitheia's operational headquarters
Ready to bring your trial to Africa?
Tell us about your protocol and therapeutic area — we'll follow up with a feasibility outlook within two business days.